REGN Q2 2025 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.7B+3.6% YoY

Gross Profit

$3.1B85.6% margin

Operating Income

$1.1B29.4% margin

Net Income

$1.4B37.9% margin

EPS (Diluted)

$12.81

QoQ Revenue Growth

+21.4%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$968M

Stock-Based Comp.

$252M

Balance Sheet

Total Assets

$38.2B

Total Liabilities

$8.3B

Stockholders' Equity

$29.9B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$3.5B	+3.6%
Gross Profit	$3.1B	$3.1B	+2.6%
Operating Income	$1.1B	$1.1B	+0.9%
Net Income	$1.4B	$1.4B	-2.8%

Revenue Segments

Collaboration Revenue

$1.9B51%

Product

$1.6B44%

Product and Service, Other

$184M5%